Physician profile
John Edward Sylvester
NPI 1508880337
$205,012.91
in general payments reported to CMS, 2019-2025
27 companies · $29K in 2025
The $29K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $39K · 2021: $31K · 2022: $40K · 2023: $5,309 · 2024: $34K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $60K · Food and Beverage: $3,422 · Acquisitions: $2,572 · Travel and Lodging: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $59,925.00 |
| Food and Beverage | $3,422.08 |
| Acquisitions | $2,571.88 |
| Travel and Lodging | $2,281.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theragenics Corporation | $155,357.10 | 2019-2025 | |
| Boston Scientific Corporation | $38,410.46 | 2019-2025 | Spaceoar Vue System - 10ml, Spaceit Hydrogel System, Spaceoar System |
| Elekta, INC. | $4,218.34 | 2019-2024 | |
| Isoray, INC | $2,738.94 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $1,121.77 | 2025 | |
| Palette Life Sciences, INC. | $755.08 | 2021 | |
| Bioprotect Medical, INC. | $280.21 | 2025 | Bioprotect Balloon Implant System |
| Blue Earth Diagnostics | $250.78 | 2019-2024 | |
| Teleflex LLC | $226.47 | 2022-2025 | Barrigel |
| Progenics Pharmaceuticals, INC. | $204.99 | 2023-2024 | Pylarify |
| Pfizer INC. | $201.40 | 2022-2025 | |
| Procept Biorobotics Corporation | $185.92 | 2024 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $183.26 | 2019-2024 | |
| Astellas Pharma US INC | $173.47 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $128.39 | 2022-2023 | Erleada |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $102.52 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $64.99 | 2022 | |
| Dendreon Pharmaceuticals LLC | $63.65 | 2021-2022 | |
| Angiodynamics, INC. | $57.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $49.80 | 2023 | |
| Sumitomo Pharma America, INC. | $46.26 | 2023-2024 | Orgovyx |
| Telix Pharmaceuticals | $45.38 | 2023 | Illuccix |
| Tolmar, INC. | $41.47 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $35.67 | 2019 | |
| Pharmacosmos Therapeutics INC. | $25.62 | 2025 | Monoferric |
| Abbvie INC. | $22.79 | 2024 | |
| Janssen Scientific Affairs, LLC | $20.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sylvester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.